{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-25-000076","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.979847+00:00","generated_at":"2026-05-17T01:35:09.040868+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26","bullets":["Revenue $653.0M, up slightly from $649.7M year-over-year.","GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.","Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.","GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.","CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-25-000076","json":"https://secwatch.observer/filing/0000012208-25-000076.json","markdown":"https://secwatch.observer/filing/0000012208-25-000076.md","text":"https://secwatch.observer/filing/0000012208-25-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/0000012208-25-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000076/bio-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:35:09.040868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}